PM528. The key factor in reducing prevalence of cardiovascular disease and metabolic syndrome among Japanese chronic schizophrenia

Purpose: Individuals with schizophrenia have a vastly reduced lifespan compared with the general population; comorbid cardiovascular disease (CVD) is the leading cause of death for them. Furthermore, these individuals are more likely to have metabolic syndrome-related disorders (MSDs), which increase CVD risk. We examined the medical records of long-term inpatients with schizophrenia to identify methods for preventing CVD and MSDs. Method: A retrospective survey was conducted on 56 inpatients with schizophrenia. The prevalence rates of CVD and MSDs among inpatients with schizophrenia were compared with Japanese general population data from the 2010 National Health and Nutrition Examination Survey. Then, we compared the variables influencing CVD and MSDs between firstand second-generation antipsychotic drug groups. Results: The prevalence of hyperlipidemia, diabetes mellitus, hypertension, myocardial infarction, and cerebral hemorrhage among individuals with schizophrenia was lower than that among the Japanese general population. This effect is likely attributable to the nursing care offered to individuals with schizophrenia, which includes dietary advice, moderate exercise support, and body weight and blood pressure measurement. Medication did not correlate with CVD or MSD prevalence. Discussion: Long-term hospitalization appeared to be particularly useful in preventing CVD and MSDs; thus, nursing care equivalent to that provided in hospitals can reduce the prevalence of CVD and MSDs among patients with schizophrenia. Antipsychotic drugs might have only a minor influence on CVD and MSD prevalence with reliable nursing care. Japanese psychiatric personnel should attend to outpatients with schizophrenia, as this population is increasing and receives less care than do inpatients. PM529 Three clinical distinct groups according to medication adherence in rehospitalized patients with schizophrenia Yulim Nam, MD1, Hyun Joo Shin, MD1, Gahyeon Song, MD1, Jong-il Lee, MD, PhD1, Hyun-Kyung Lee, PhD2, Shihyun Kang, MD, PhD1 1Department of Psychiatry, Seoul National Hospital, Seoul, Republic of Korea 2Department of Mental Health Research, Seoul National